The suppressive tumor microenvironment: A challenge in cancer immunotherapy

Molecular Pharmaceutics

Volumn 8, Issue 3, 2011, Pages 635-641

  Vasievich, Elizabeth A ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

immunotherapy; myeloid derived suppressor cells (MDSC); T regulatory cells (Tregs); Therapeutic vaccine; tumor associated macrophages (TAMs)

Indexed keywords

DACLIZUMAB; TRANSCRIPTION FACTOR FOXP3;

BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; HUMAN; METASTASIS; MYELOID DERIVED SUPPRESSOR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MODELS, BIOLOGICAL; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 79958293766     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1004228     Document Type: Review

References (72)

1. Small, E. J.; Schellhammer, P. F.; Higano, C. S.; Redfern, C. H.; Nemunaitis, J. J.; Valone, F. H.; Verjee, S. S.; Jones, L. A.; Hershberg, R. M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J. Clin. Oncol. 2006, 24, 3089-3094 (Pubitemid 46638945)
2. Kantoff, P. W.; Higano, C. S.; Shore, N. D.; Berger, E. R.; Small, E. J.; Penson, D. F.; Redfern, C. H.; Ferrari, A. C.; Dreicer, R.; Sims, R. B.; Xu, Y.; Frohlich, M. W.; Schellhammer, P. F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med. 2010, 363, 411-422
3. Triozzi, P. L.; Aldrich, W.; Ponnazhagan, S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists Vaccine 2010, 28, 7837-7843
4. Reinis, M. Immunotherapy of MHC class I-deficient tumors Future Oncol. 2010, 6, 1577-1589
5. Lin, W. W.; Hsieh, S. L. Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer Biochem. Pharmacol. 2011, 81, 838-847
6. Blank, C.; Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion Cancer Immunol. Immunother. 2007, 56, 739-745 (Pubitemid 46348742)
7. Coussens, L. M.; Werb, Z. Inflammation and cancer Nature 2002, 420, 860-867 (Pubitemid 36019639)
8. Solinas, G.; Schiarea, S.; Liguori, M.; Fabbri, M.; Pesce, S.; Zammataro, L.; Pasqualini, F.; Nebuloni, M.; Chiabrando, C.; Mantovani, A.; Allavena, P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility J. Immunol. 2010, 185, 642-652
9. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539-545 (Pubitemid 32173595)
10. Klimp, A. H.; de Vries, E. G.; Scherphof, G. L.; Daemen, T. A potential role of macrophage activation in the treatment of cancer Crit. Rev. Oncol. Hematol. 2002, 44, 143-161 (Pubitemid 36159043)
11. Hembruff, S. L.; Jokar, I.; Yang, L.; Cheng, N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms Neoplasia 2010, 12, 425-433
12. Zijlmans, H. J.; Fleuren, G. J.; Baelde, H. J.; Eilers, P. H.; Kenter, G. G.; Gorter, A. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2 J. Pathol. 2006, 208, 507-517 (Pubitemid 43329337)
13. Miotto, D.; Boschetto, P.; Bononi, I.; Milani, G.; Legorini, C.; Cavallesco, G.; Lo Cascio, N.; Zeni, E.; Fabbri, L. M.; Mapp, C. E. CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer Respir. Med. 2007, 101, 1738-1743 (Pubitemid 46930709)
14. Kuroda, T.; Kitadai, Y.; Tanaka, S.; Yang, X.; Mukaida, N.; Yoshihara, M.; Chayama, K. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment Clin. Cancer Res. 2005, 11, 7629-7636 (Pubitemid 41611603)
15. Loberg, R. D.; Ying, C.; Craig, M.; Yan, L.; Snyder, L. A.; Pienta, K. J. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration Neoplasia 2007, 9, 556-562 (Pubitemid 47121829)
16. Bailey, C.; Negus, R.; Morris, A.; Ziprin, P.; Goldin, R.; Allavena, P.; Peck, D.; Darzi, A. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer Clin. Exp. Metastasis 2007, 24, 121-130 (Pubitemid 46669245)
17. Kross, K. W.; Heimdal, J. H.; Olsnes, C.; Olofson, J.; Aarstad, H. J. Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue Acta Otolaryngol. 2007, 127, 532-539 (Pubitemid 46633782)
18. Roca, H.; Varsos, Z. S.; Sud, S.; Craig, M. J.; Ying, C.; Pienta, K. J. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization J. Biol. Chem. 2009, 284, 34342-34354
19. Allavena, P.; Sica, A.; Solinas, G.; Porta, C.; Mantovani, A. The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages Crit. Rev. Oncol. Hematol. 2008, 66, 1-9 (Pubitemid 351324128)
20. Werno, C.; Menrad, H.; Weigert, A.; Dehne, N.; Goerdt, S.; Schledzewski, K.; Kzhyshkowska, J.; Brune, B. Knockout of HIF-1alpha in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses Carcinogenesis 2010, 31, 1863-1872
21. Koga, M.; Kai, H.; Egami, K.; Murohara, T.; Ikeda, A.; Yasuoka, S.; Egashira, K.; Matsuishi, T.; Kai, M.; Kataoka, Y.; Kuwano, M.; Imaizumi, T. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice Biochem. Biophys. Res. Commun. 2008, 365, 279-284 (Pubitemid 350137285)
22. Gazzaniga, S.; Bravo, A. I.; Guglielmotti, A.; van Rooijen, N.; Maschi, F.; Vecchi, A.; Mantovani, A.; Mordoh, J.; Wainstok, R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft J. Invest. Dermatol. 2007, 127, 2031-2041 (Pubitemid 47075380)
23. Kagaya, T.; Nakamoto, Y.; Sakai, Y.; Tsuchiyama, T.; Yagita, H.; Mukaida, N.; Kaneko, S. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer Cancer Gene Ther. 2006, 13, 357-366
24. Guiducci, C.; Vicari, A. P.; Sangaletti, S.; Trinchieri, G.; Colombo, M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection Cancer Res. 2005, 65, 3437-3446 (Pubitemid 40524630)
25. Bolpetti, A.; Silva, J. S.; Villa, L. L.; Lepique, A. P. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth BMC Immunol. 2010, 11, 27
26. Ito, T.; Schaller, M.; Hogaboam, C. M.; Standiford, T. J.; Chensue, S. W.; Kunkel, S. L. TLR9 activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response Eur. J. Immunol. 2007, 37, 2847-2855 (Pubitemid 47578304)
27. Luo, Y.; Zhou, H.; Krueger, J.; Kaplan, C.; Lee, S. H.; Dolman, C.; Markowitz, D.; Wu, W.; Liu, C.; Reisfeld, R. A.; Xiang, R. Targeting tumor-associated macrophages as a novel strategy against breast cancer J. Clin. Invest. 2006, 116, 2132-2141 (Pubitemid 44162322)
28. Gabrilovich, D. I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 2009, 9, 162-174
29. Schmid, M. C.; Varner, J. A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation J. Oncol. 2010, 2010, 201026
30. Yang, R.; Roden, R. B. S. The Terminology Issue for Myeloid-Derived Suppressor Cells Cancer Res. 2007, 67, 426
31. Yang, R.; Cai, Z.; Zhang, Y.; Yutzy, W. H. t.; Roby, K. F.; Roden, R. B. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells Cancer Res. 2006, 66, 6807-6815 (Pubitemid 44085641)
32. Movahedi, K.; Guilliams, M.; Van den Bossche, J.; Van den Bergh, R.; Gysemans, C.; Beschin, A.; De Baetselier, P.; Van Ginderachter, J. A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity Blood 2008, 111, 4233-4244
33. Youn, J. I.; Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity Eur. J. Immunol. 2010, 40, 2969-2975
34. Habibi, M.; Kmieciak, M.; Graham, L.; Morales, J. K.; Bear, H. D.; Manjili, M. H. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis Breast Cancer Res. Treat. 2009, 114, 423-431
35. Yang, L.; Huang, J.; Ren, X.; Gorska, A. E.; Chytil, A.; Aakre, M.; Carbone, D. P.; Matrisian, L. M.; Richmond, A.; Lin, P. C.; Moses, H. L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis Cancer Cell 2008, 13, 23-35 (Pubitemid 350309741)
36. Kim, H. S.; Park, H. M.; Park, J. S.; Sohn, H. J.; Kim, S. G.; Kim, H. J.; Oh, S. T.; Kim, T. G. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model Vaccine 2010, 28, 7787-7796
37. Murdoch, C.; Muthana, M.; Coffelt, S. B.; Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis Nat. Rev. Cancer 2008, 8, 618-631
38. Kusmartsev, S.; Nefedova, Y.; Yoder, D.; Gabrilovich, D. I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species J. Immunol. 2004, 172, 989-999 (Pubitemid 38113758)
39. Li, H.; Han, Y.; Guo, Q.; Zhang, M.; Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1 J. Immunol. 2009, 182, 240-249
40. Song, X.; Krelin, Y.; Dvorkin, T.; Bjorkdahl, O.; Segal, S.; Dinarello, C. A.; Voronov, E.; Apte, R. N. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells J. Immunol. 2005, 175, 8200-8208 (Pubitemid 41798384)
41. Young, M. R.; Kolesiak, K.; Wright, M. A.; Gabrilovich, D. I. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor Clin. Exp. Metastasis 1999, 17, 881-888
42. Serafini, P.; Carbley, R.; Noonan, K. A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells Cancer Res. 2004, 64, 6337-6343 (Pubitemid 39129439)
43. Bronte, V.; Apolloni, E.; Cabrelle, A.; Ronca, R.; Serafini, P.; Zamboni, P.; Restifo, N. P.; Zanovello, P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells Blood 2000, 96, 3838-3846
44. Sinha, P.; Clements, V. K.; Bunt, S. K.; Albelda, S. M.; Ostrand-Rosenberg, S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response J. Immunol. 2007, 179, 977-983
45. Ohkusu-Tsukada, K.; Ohta, S.; Kawakami, Y.; Toda, M. Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of myeloid-derived suppressor cells in cancer immunotherapy Int. J. Cancer 2011, 128, 119-131
46. Mirza, N.; Fishman, M.; Fricke, I.; Dunn, M.; Neuger, A. M.; Frost, T. J.; Lush, R. M.; Antonia, S.; Gabrilovich, D. I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Res. 2006, 66, 9299-9307 (Pubitemid 44521152)
47. Gonzalez-Aparicio, M.; Alzuguren, P.; Mauleon, I.; Medina-Echeverz, J.; Hervas-Stubbs, S.; Mancheno, U.; Berraondo, P.; Crettaz, J.; Gonzalez-Aseguinolaza, G.; Prieto, J.; Hernandez-Alcoceba, R. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice Gut 2011, 60, 341-349
48. Suzuki, E.; Kapoor, V.; Jassar, A. S.; Kaiser, L. R.; Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin. Cancer Res. 2005, 11, 6713-6721 (Pubitemid 41339014)
49. Yang, Z.-Z.; Ansell, S. M. The Role of Treg Cells in the Cancer Immunological Response Am. J. Immunol. 2009, 5, 17-28
50. Ahmadzadeh, M.; Felipe-Silva, A.; Heemskerk, B.; Powell, D. J., Jr.; Wunderlich, J. R.; Merino, M. J.; Rosenberg, S. A. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions Blood 2008, 112, 4953-4960
51. Chen, W.; Yan, W.; Huang, L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid Cancer Immunol. Immunother. 2008, 57, 517-530 (Pubitemid 351170535)
52. Goforth, R.; Salem, A. K.; Zhu, X.; Miles, S.; Zhang, X. Q.; Lee, J. H.; Sandler, A. D. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma Cancer Immunol. Immunother. 2009, 58, 517-530
53. Woo, E. Y.; Chu, C. S.; Goletz, T. J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S. C.; Kaiser, L. R.; June, C. H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res. 2001, 61, 4766-4772 (Pubitemid 32691889)
54. Lagouros, E.; Salomao, D.; Thorland, E.; Hodge, D. O.; Vile, R.; Pulido, J. S. Infiltrative T regulatory cells in enucleated uveal melanomas Trans. Am. Ophthalmol. Soc. 2009, 107, 223-228
55. Valdman, A.; Jaraj, S. J.; Comperat, E.; Charlotte, F.; Roupret, M.; Pisa, P.; Egevad, L. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue APMIS 2010, 118, 360-365
56. El Andaloussi, A.; Han, Y.; Lesniak, M. S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors J. Neurosurg. 2006, 105, 430-437 (Pubitemid 44358755)
57. Kobayashi, N.; Hiraoka, N.; Yamagami, W.; Ojima, H.; Kanai, Y.; Kosuge, T.; Nakajima, A.; Hirohashi, S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis Clin. Cancer Res. 2007, 13, 902-911 (Pubitemid 46340366)
58. Eikawa, S.; Ohue, Y.; Kitaoka, K.; Aji, T.; Uenaka, A.; Oka, M.; Nakayama, E. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6 J. Immunol. 2010, 185, 6734-6740
59. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 2004, 10, 942-949 (Pubitemid 39273735)
60. Jacobs, J. F.; Idema, A. J.; Bol, K. F.; Grotenhuis, J. A.; de Vries, I. J.; Wesseling, P.; Adema, G. J. Prognostic significance and mechanism of Treg infiltration in human brain tumors J. Neuroimmunol. 2010, 225, 195-199
61. Mailloux, A. W.; Clark, A. M.; Young, M. R. NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells Int. J. Cancer 2010, 127, 2598-2611
62. Tan, M. C.; Goedegebuure, P. S.; Belt, B. A.; Flaherty, B.; Sankpal, N.; Gillanders, W. E.; Eberlein, T. J.; Hsieh, C. S.; Linehan, D. C. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer J. Immunol. 2009, 182, 1746-1755
63. Levings, M. K.; Roncarolo, M. G. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties J. Allergy Clin. Immunol. 2000, 106, S109-112
64. O'Garra, A.; Vieira, P. L.; Vieira, P.; Goldfeld, A. E. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage J. Clin. Invest. 2004, 114, 1372-1378 (Pubitemid 40385564)
65. Jacobs, C.; Duewell, P.; Heckelsmiller, K.; Wei, J.; Bauernfeind, F.; Ellermeier, J.; Kisser, U.; Bauer, C. A.; Dauer, M.; Eigler, A.; Maraskovsky, E.; Endres, S.; Schnurr, M. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma Int. J. Cancer 2011, 128, 897-907
66. Curtin, J. F.; Candolfi, M.; Fakhouri, T. M.; Liu, C.; Alden, A.; Edwards, M.; Lowenstein, P. R.; Castro, M. G. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials PLoS One 2008, 3, e1983
67. Rech, A. J.; Vonderheide, R. H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann. N.Y. Acad. Sci. 2009, 1174, 99-106
68. Morse, M. A.; Hobeika, A. C.; Osada, T.; Serra, D.; Niedzwiecki, D.; Lyerly, H. K.; Clay, T. M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008, 112, 610-618
69. Rasku, M. A.; Clem, A. L.; Telang, S.; Taft, B.; Gettings, K.; Gragg, H.; Cramer, D.; Lear, S. C.; McMasters, K. M.; Miller, D. M.; Chesney, J. Transient T cell depletion causes regression of melanoma metastases J. Transl. Med. 2008, 6, 12
70. Matsushita, N.; Pilon-Thomas, S. A.; Martin, L. M.; Riker, A. I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model J. Immunol. Methods 2008, 333, 167-179
71. Quezada, S. A.; Peggs, K. S.; Curran, M. A.; Allison, J. P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells J. Clin. Invest. 2006, 116, 1935-1945 (Pubitemid 44033317)
72. Kraman, M.; Bambrough, P. J.; Arnold, J. N.; Roberts, E. W.; Magiera, L.; Jones, J. O.; Gopinathan, A.; Tuveson, D. A.; Fearon, D. T. Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-{alpha} Science 2010, 330, 827-830